Associate Professor
Clinical Research Division, Fred Hutch
Dr. Scott Tykodi specializes in translating immunotherapy advances from the laboratory into the clinic. He has led numerous clinical trials evaluating novel, immune-based therapeutics for patients with kidney cancer or other solid tumors. Dr. Tykodi is developing a new cellular immunotherapy for kidney cancer aimed at a marker called 5T4, which is found on the surface of almost all kidney cancer cells and only rarely on healthy adult cells.
For more information, contact:
Samantha Kiriluk
206-606-7341
smlim@seattlecca.org
Associate Professor, Division of Medical Oncology
University of Washington School of Medicine
Fellowship: University of Washington Medical Oncology, 2000-2003
Residency: Barnes Hospital Internal Medicine, 1997-2000
Washington University School of Medicine, 1997
Study Number: RG1005214
Phase: III
Study Number: RG1718060
Phase: II
The Media Relations team at Fred Hutch is available to assist members of the news media who would like to arrange interviews with faculty.
Email media@fredhutch.org or call 206.667.2210